Johnson & Johnson, which has started its clinical trials for Ebola vaccine, was given $115 million (100 million euro) from Europe’s Innovative Medicines Initiative to speed up its development.
The has started its clinical trials earlier this week of its two-injection vaccine, which uses a booster from Denmark’s Bavarian Nordic. This will be the third vaccine to enter human testing phase.
J&J had set aside $200 million in October to accelerate its Ebola vaccine program. J&J said it would join other institutes like the London School of Hygiene & Tropical Medicine, the University of Oxford and the Institut National de la Sante et de la Recherche Medicale to form consortia working on different aspects of the vaccine.
Europe’s Innovative Medicines Initiative (IMI), which has granted 100 million euro is a public-private scheme of the European Commission and the pharmaceuticals industry. The IMI has announced two months ago a budget of 280 million euros for Ebola research.
Apart from J&J vaccine, the other two Ebola experimental vaccines are from GlaxoSmithKline and another from NewLink and Merck.